Classification and/or possible targeted therapies of hematological neoplasms such as hairy cell leukemia, Langerhans cell histiocytosis, Erdheim-Chester disease
Real-Time PCR Amplification and Detection
BRAF
BRAF mutation
Erdheim-Chester disease
Hairy Cell leukemia
Langerhans cell histiocytosis
MBRAF
V600E
V600K
V600R
V600D
V600M
Bone Marrow
Specimen must arrive within 7 days of collection.
The following information is required:
1. Pertinent clinical history
2. Clinical or morphologic suspicion
3. Date of collection
4. Specimen source
Container/Tube: Lavender top (EDTA) or yellow top (ACD solution B)
Specimen Volume: 2 mL
Collection Instructions:
1. Invert several times to mix bone marrow.
2. Send bone marrow specimen in original tube. Do not aliquot.
3. Label specimen as bone marrow.
1 mL
Gross hemolysis | Reject |
Moderately to severely clotted | Reject |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Bone Marrow | Ambient (preferred) | 7 days | |
Refrigerated | 7 days |
Classification and/or possible targeted therapies of hematological neoplasms such as hairy cell leukemia, Langerhans cell histiocytosis, Erdheim-Chester disease
This test uses DNA extracted from the bone marrow to test for the presence of BRAF V600E/D and V600K/R/M alterations. BRAF mutations occur in many different types of human cancers. Testing for BRAF mutations in bone marrow specimens facilitates classification and possible targeted therapies of hematological neoplasms, such as hairy cell leukemia, Langerhans cell histiocytosis, and Erdheim-Chester disease. This is test is not designed for detection of BRAF mutations in liquid biopsy of tumors.
An interpretive report will be provided
An interpretive report will be provided.
Results will be characterized as positive, negative, or indeterminate for a V600 somatic mutation.
Test results should be interpreted in context of clinical findings and other laboratory data. If results obtained do not match other clinical or laboratory findings, please contact the laboratory for possible interpretation. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.
1. Maitre E, Cornet E, Troussard X. Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94(12):1413-1422
2. Rodriguez-Galindo C, Allen CE. Langerhans cell histiocytosis. Blood. 2020;135(16):1319-1331
3. Haroche J, Cohen-Aubart F, Amoura Z. Erdheim-Chester disease. Blood. 2020;135(16):1311-1318
Polymerase chain reaction-based assay using bone marrow sample. This test detects the most common mutation V600E and other variants at the same codon. The limit of detection for this assay is approximately 1%. The mutation is reported using the current standard nomenclature.(Unpublished Mayo method)
Monday through Friday
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.
81210
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
MBRAF | BRAF V600 Somatic Mutation, BM | 85101-4 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
616930 | Result | 85101-4 |
616928 | Interpretation | 59465-5 |
616939 | Signing Pathologist | 18771-6 |
616936 | Method Summary | 85069-3 |
616934 | Sample ID | 80398-1 |
616938 | Disclaimer | 62364-5 |
616931 | Indication for Testing | 42349-1 |
616952 | Specimen | 31208-2 |
616933 | Source | 31208-2 |